| Code | CSB-RA023981MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to INBRX-106, targeting TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a co-stimulatory receptor expressed primarily on activated T cells that plays a critical role in T cell activation, proliferation, and survival. Upon binding its ligand OX40L, this receptor enhances T cell-mediated immune responses and promotes the differentiation of effector and memory T cells. TNFRSF4 has emerged as an important therapeutic target in immuno-oncology, as its activation can enhance anti-tumor immunity by stimulating cytotoxic T lymphocytes and reducing regulatory T cell suppressive activity.
INBRX-106 is a clinical-stage agonistic antibody engineered to activate TNFRSF4 signaling and enhance T cell responses against tumors. This biosimilar provides researchers with a valuable tool for investigating OX40-mediated immune modulation, studying T cell biology, and exploring combination immunotherapy approaches in preclinical cancer models. It supports investigations into checkpoint modulation and adaptive immunity mechanisms relevant to oncology and autoimmune disease research.
There are currently no reviews for this product.